GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (XTER:EVT) » Definitions » 3-Year FCF Growth Rate

Evotec SE (XTER:EVT) 3-Year FCF Growth Rate : -42.20% (As of Dec. 2023)


View and export this data going back to 1999. Start your Free Trial

What is Evotec SE 3-Year FCF Growth Rate?

Evotec SE's Free Cash Flow per Share for the three months ended in Dec. 2023 was €-0.25.

During the past 12 months, Evotec SE's average Free Cash Flow per Share Growth Rate was -925.20% per year. During the past 3 years, the average Free Cash Flow per Share Growth Rate was -42.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Evotec SE was 230.20% per year. The lowest was -95.80% per year. And the median was 0.10% per year.


Competitive Comparison of Evotec SE's 3-Year FCF Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Evotec SE's 3-Year FCF Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Evotec SE's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Evotec SE's 3-Year FCF Growth Rate falls into.



Evotec SE 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Evotec SE  (XTER:EVT) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Evotec SE 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Evotec SE's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Evotec SE (XTER:EVT) Business Description

Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.
Executives
Dr. Werner Lanthaler Board of Directors

Evotec SE (XTER:EVT) Headlines